IB Net Payout Yields Model

InterCure: True International Cannabis Play

  • InterCure offers a pure play on the European cannabis market with a focus on Israel.
  • The company went public via a SPAC in April and now trades below the PIPE price at only $8.
  • The stock is cheap at only 2x EV/'22 sales targets.
  • This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Learn More »
The cannabis market is ripe with investment opportunities whether in the U.S. or Canada, but very few good investments exist for companies focused outside of North America. After closing a SPAC deal, InterCure (OTCPK:IRCLF) offers an impressive opportunity to invest in European growth via a small Israeli company. The stock is a solid buy considering the company doesn't come with an expensive price tag like most Canadian cannabis companies playing in European cannabis markets.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

 Update - July 25

The Israeli cannabis company could uplift to the Nasdaq as soon as this week. Investors should watch for a catalyst when this occurs with the stock only trading at $6.25 here after hitting a high of nearly $10. 


Popular posts from this blog

Occidental: Still Producing Too Much Oil

ChargePoint: Low Quality Beat

Aurora Cannabis: Deal Or No Deal